Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

NCT06573398 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Pancreatic Ductal

Interventions

COMBINATION_PRODUCT: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin

Sponsor

Ruijin Hospital